Resources
Partnerships with Bayer - Targeting CKD
Addressing unmet need in chronic kidney disease and cardiovascular disease
Tackling CVD, including prevention, early detection and treatment remains a key national priority outlined in the NHS Long Term Plan.[1] CKD is recognised as a major risk factor for the development of CVD.[2] Currently there is significant unmet need across the detection and management of these conditions. Access the resources below to better understand why CVD and CKD should be prioritised and how Bayer can support the NHS to address the burden of these diseases.
Partnerships with Bayer - Targeting CKD
Abbreviations
CKD - chronic kidney disease
CVD - cardiovascular disease
View Kerendia®▼ (finerenone) Prescribing Information
PP-MACS-GB-0317 | November 2024